Health and Fitness Health and Fitness
Wed, September 29, 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc to Report Fourth-Quarter Results on November 9, 2010
[ Wed, Sep 29th 2010 ] - Market Wire
BD Diagnostics and Bruker Collaborate to Improve .. fication and Antimicrobial Susceptibility Testing
[ Wed, Sep 29th 2010 ] - Market Wire
Wellstar International, Inc. Announces the Result .. n of the Duke University Study Have Been Accepted
Tue, September 28, 2010
[ Tue, Sep 28th 2010 ] - Market Wire
Prospect Medical Holdings, Inc. Announces End of aGo-Shopa Period
[ Tue, Sep 28th 2010 ] - Market Wire
Medtronic Advances Research on Drug-Eluting Balloons for Coronary and Peripheral Artery Disease
[ Tue, Sep 28th 2010 ] - Market Wire
HealthSpring, Inc. Announces the Addition of John T. Fox to Its Board of Directors
[ Tue, Sep 28th 2010 ] - Market Wire
Medtronica?s Insertable Cardiac Monitor Documented Arrhythmias in Post-Heart Attack Patients
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien far Apresentao na conferncia "Jefferies European Healthcare Conference"
[ Tue, Sep 28th 2010 ] - Market Wire
Aetna Becomes First Georgia Insurer to Cover Medically Fragile Children for aDream Housea?
[ Tue, Sep 28th 2010 ] - Market Wire
Nicusa Capital Calls for Leadership Changes at BioClinica
[ Tue, Sep 28th 2010 ] - Market Wire
Synergetics USA to Present at Craig-Hallum Capital Group 2010 Alpha Select Conference
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien presenteert tijdens congres Jefferies European Healthcare
[ Tue, Sep 28th 2010 ] - Market Wire
CellCyte Genetics Corp. Announces the Appointment of Douglas Pat Cerretti, Ph.D. to President
[ Tue, Sep 28th 2010 ] - Market Wire
Biojector®2000 Utilized in a Human Clinical Trial of DNA-MVA HIV Vaccine
[ Tue, Sep 28th 2010 ] - Market Wire
XenoPort Announces Presentation of New Data for XP21279 at World Parkinson Congress
[ Tue, Sep 28th 2010 ] - Market Wire
Amedisys Receives Civil Investigative Demand from the U.S. Department of Justice
[ Tue, Sep 28th 2010 ] - Market Wire
Health Net, Inc. to Hold Conference Call and Webc .. st to Discuss Third Quarter 2010 Earnings Results
[ Tue, Sep 28th 2010 ] - Market Wire
St. Jude Medical Announces Principal Investigator .. r Aortic Valve Implantation (TAVI) Clinical Trial
[ Tue, Sep 28th 2010 ] - Market Wire
Rochea?s New RTCA Cardio Instrument for Label-Free Functional Cardiomyocyte Toxicity Testing
[ Tue, Sep 28th 2010 ] - Market Wire
International Stem Cell Corporation Announces Sig .. ation of the First Bank of Immune-Matched Human P
[ Tue, Sep 28th 2010 ] - Market Wire
ARIAD to Present at the Jefferies Global SpecPharma and European Healthcare Conference
[ Tue, Sep 28th 2010 ] - Market Wire
Unigene Expands Board of Directors; Elects Joel A. Tune as Director
[ Tue, Sep 28th 2010 ] - Market Wire
Oncolytics Biotech Inc. Announces Issuance of Key U.S. Patent
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien unter den Referenten auf der Jefferies European Healthcare Conference
[ Tue, Sep 28th 2010 ] - Market Wire
Presentazione di Covidien alla Jefferies European Healthcare Conference
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien effectuera une pr©sentation dans le cad .. europ©enne de Jefferies sur les soins de sant©
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien se presentar en la Conferencia Europea sobre el cuidado de la salud Jefferies
[ Tue, Sep 28th 2010 ] - Market Wire
Covidien to Present at Jefferies European Healthcare Conference
[ Tue, Sep 28th 2010 ] - Market Wire
AngioDynamics to Report Fiscal 2011 First Quarter .. sults and Hold Conference Call on October 7, 2010
[ Tue, Sep 28th 2010 ] - Market Wire
AVEO Pharmaceuticals, Inc. to Present at Upcoming .. cology Medical Meetings and Investment Conference

AVEO Pharmaceuticals, Inc. to Present at Upcoming Oncology Medical Meetings and Investment Conference


Published on 2010-09-28 03:40:26 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company will have a presence at two upcoming oncology medical meetings and Citia™s 5th Annual Biotech Day investment conference.

"Hidden Gems in Hematology/Oncology: A Survey of What to Keep an Eye on"

Data from AVEOa™s tivozanib clinical development program will be presented at the following medical meetings:

  • 9th International Kidney Cancer Symposium (IKCS), October 1-2, 2010 at the Swiss'tel in Chicago.
  • 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

In addition, William Slichenmyer, M.D., Sc.M., chief medical officer of AVEO, is scheduled to be featured on the panel, aHidden Gems in Hematology/Oncology: A Survey of What to Keep an Eye on,a on Tuesday, October 5, 2010 at 3:00 p.m. EDT as part of Citia™s 5th Annual Biotech Day investment conference at the Westin Waterfront Hotel in Boston.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The companya™s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOa™s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets includingHGF, ErbB3, RON, Notch andFGFR. For more information, please visit the company's website at [ www.aveopharma.com ].

Contributing Sources